Table 1

Growth Inhibition (IC50)a of 1,4-disubstituted Aminoanthraquinones against wild-type versus resistant human ovarian carcinoma cell lines

AnthraquinoneA2780
2780AD
2780/cp70
B1
(nm)(nm)RFb(nm)RF(nm)RF
ZP2571.69 ± 0.14c40.4 ± 6.6241.22 ± 0.451.00.93 ± 0.171.0
ZP2650.71 ± 0.3221.2 ± 1.5301.55 ± 0.242.11.79 ± 0.242.5
ZP2751.12 ± 0.14144.5 ± 7.51292.55 ± 0.442.22.19 ± 0.652.0
Alchemix4.01 ± 0.5716.0 ± 1.72411.8 ± 1.42.97.02 ± 0.641.7
ZP282M3.04 ± 0.57245.8 ± 11.88150.2 ± 3.916.519.6 ± 2.66.4
ZP285M0.93 ± 0.31573.3 ± 132.661614.3 ± 1.015.35.81 ± 1.536.2
ZP289M7.56 ± 0.882637 ± 154348125.9 ± 20.816.666.0 ± 4.58.7
Cisplatin340.0 ± 603020 ± 22092620 ± 7307.71830 ± 2305.3
Doxorubicin4.98 ± 1.074860 ± 51097613.3 ± 0.92.611.7 ± 1.02.3
  • a IC50 is the concentration of drug (nm) required to inhibit cell growth by 50%.

  • b SE of the mean (n = 3).

  • c RF, resistance factor (IC50 in resistant cell line/IC50 in parent cell line).